Actavis plans entry to biosimilars market with Bioton agreement

Home/Pharma News | Posted 24/09/2010 post-comment0 Post your comment

In a press release on 7 September 2010, Icelandic generics’ manufacturer Actavis announced that it plans to enter into the field of biosimilars with an agreement with Polish biotechnology company, Bioton.

picture04

The agreement will involve the sale of 51% of Bioton’s shares in Biopartners Holdings to Actavis, giving it a majority share in the company.

Biopartners is a Swiss-based biopharmaceutical company. Its recombinant human growth hormone (rhGH), Valtropin, was one of the first biosimilars to receive marketing authorisation from the EMA. Biopartners is also on track to be the first company to submit a sustained-release formulation of rhGH, which will cut the number of self-administered injections from once-a-day to once-a-week - a major breakthrough in hGH treatment.

Actavis CEO, Dr Claudio Albrecht, commented that “by entering into biosimilars the generic companies gain access to a portfolio that requires a new approach to development and marketing. We will have generic companies investing significantly more in research and we will see originator companies developing generics. Only the large generic players such as Teva, Sandoz, Mylan and Actavis have the capability to do this, either by themselves or in partnership with originators”.

Actavis have stated that they want to be selective with their biologic target portfolio, highlighting endocrinology (a branch of biology and medicine dealing with the endocrine system), oncology and insulin as areas of interest for them.

Actavis has until 1 November 2010 to perform its due diligence of Biopartners and finalise the agreement.

Actavis is the latest in a string of generics companies looking to gain a foothold in the, what promises to be, lucrative biosimilars market.

Related articles

Cipla invests in biosimilars

Cipla enters the biosimilars market

References

Actavis Press Releases. Actavis plans to enter into Biosimilars. 7 September 2010.

Bioton Investor Reports. Current report 2010/53 dated 06.09.2010. Confidential information (conclusion of agreement between BIOTON S.A. and Actavis Group Hf). 6 September 2010.

comment icon Comments (0)
Post your comment
Related content
Collaborations to commercialize oncology biosimilars
Cancer Cell V13I20
Home/Pharma News Posted 22/10/2021
Licensing agreements signed for ustekinumab biosimilars
IBD 1
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010